

Mitochondrial Antibody Testing

| Table of Content |
|---|
| Purpose |
| Description & Definitions |
| Criteria |
| Coding |
| Document History |
| References |
| Special Notes |
| Keywords |

| | |
|-------------------------|-------------|
| <u>Effective Date</u> | 10/2022 |
| <u>Next Review Date</u> | 10/15/2024 |
| <u>Coverage Policy</u> | Medical 180 |
| <u>Version</u> | 2 |

All requests for authorization for the services described by this medical policy will be reviewed per Early and Periodic Screening, Diagnostic and Treatment (EPSDT) guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to be medically necessary to correct or ameliorate the member’s condition. Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.*.

Purpose:

This policy addresses the medical necessity of Mitochondrial antibody testing.

Description & Definitions:

Mitochondrial antibody (eg, M2) testing for either celiac disease or primary biliary cholangitis (primary biliary cirrhosis)

Criteria:

Mitochondrial Antibody Testing is considered medically necessary for **all of the following**:

- Primary Biliary Cholangitis

Mitochondrial Antibody Testing is considered **not medically necessary** for uses other than those listed in the clinical criteria, to include but not limited to:

- Celiac disease

Coding:

Medically necessary with criteria:

| Coding | Description |
|--------|---------------------------------------|
| 86381 | Mitochondrial antibody (eg, M2), each |

Considered Not Medically Necessary:

| Coding | Description |
|--------|-------------|
| | None |

U.S. Food and Drug Administration (FDA) - approved only products only.

Document History:

Revised Dates:

- N/A

Reviewed Dates:

- 2023: October

Effective Date:

- October 2002

References:

Including but not limited to: Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

(2023). Retrieved Sep 26, 2023, from Hayes, Inc:

<https://evidence.hayesinc.com/search?q=%257B%2522text%2522:%2522mitochondrial%2520antibody%2522,%2522title%2522:null,%2522termsource%2522:%2522searchbar%2522,%2522page%2522:%257B%2522page%2522:0,%2522size%2522:50%257D,%2522type%2522:%2522all%2522,%2522sou>

(2023). Retrieved Sep 27, 2023, from Centers for Medicare and Medicaid Services:

[https://www.cms.gov/medicare-coverage-database/search-results.aspx?keyword=Mitochondrial%20antibody&keywordType=starts&areald=s53&docType=NCA,CAL,NCD,ME](https://www.cms.gov/medicare-coverage-database/search-results.aspx?keyword=Mitochondrial%20antibody&keywordType=starts&areald=s53&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance)

(2023). Retrieved Sep 27, 2023, from Carelon Medical Benefits Management:

[https://guidelines.carelonmedicalbenefitsmanagement.com/?s=Mitochondrial+antibody&et_pb_searchform_submi](https://guidelines.carelonmedicalbenefitsmanagement.com/?s=Mitochondrial+antibody&et_pb_searchform_submit=et_search_proccess&et_pb_search_cat=11%2C1%2C96&et_pb_include_posts=yes)

(2023, Jun 27). Retrieved Sep 27, 2023, from MCG: <https://careweb.careguidelines.com/ed27/index.html>

(2023). Retrieved Sep 28, 2023, from Department of Medical Assistance Services:

<https://vamedicaid.dmas.virginia.gov/manuals/provider-manuals-library#gsc.tab=0&gsc.q=mitochondrial%20antibody&gsc.sort=>

Mitochondrial Antibodies (M2), Serum. (2023). Retrieved Sep 28, 2023, from Mayo Clinic Laboratories:

<https://logan.testcatalog.org/show/MA>

Poupon, R. (2023, Mar 15). Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis.

Retrieved Sep 26, 2023, from UpToDate: https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-prognosis-of-primary-biliary-cholangitis?search=mitochondrial%20antibody&source=search_result&selectedTitle=3~150&usage_type=default&display_rank=3#

(2023). Retrieved Sep 28, 2023, from Google, Inc:

<https://www.google.com/search?q=Professional+recommendations+for+Mitochondrial+Antibody+Testing&safe=str>

Special Notes: *

This medical policy express Sentara Health Plan's determination of medically necessity of services, and they are based upon a review of currently available clinical information. These policies are used when no specific guidelines for coverage are provided by the Department of Medical Assistance Services of Virginia (DMAS). Medical Policies may be superseded by state Medicaid Plan guidelines. Medical policies are not a substitute for clinical judgment or for any prior authorization requirements of the health plan. These policies are not an explanation of benefits.

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

The Early and Periodic Screening, Diagnostic and Treatment (EPSDT) covers services, products, or procedures for children, if those items are determined to be medically necessary to "correct or ameliorate" (make better) a defect, physical or mental illness, or condition (health problem) identified through routine medical screening or examination, regardless of whether coverage for the same service or support is an optional or limited service under the state plan. Children enrolled in the FAMIS Program are not eligible for all EPSDT treatment services. All requests for authorization for the services described by this medical policy will be reviewed per EPSDT guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to be medically necessary to correct or ameliorate the member's condition. *Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.*

Keywords:

SHP Mitochondrial Antibody Testing, SHP Medical 180, Celiac disease, Primary Biliary Cholangitis